 SOUTH SAN FRANCISCO, Calif., June 21, 2021 GLOBE NEWSWIRE -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Companys lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. 